A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs.

ABSTRACT:

Background

We developed a new predictive staging system to explore the heterogeneity of survival in newly diagnosed multiple myeloma (NDMM) patients in the real world.

Methods

In this retrospective study, we evaluated the predictive value of cytogenetic abnormal and clinical data in 375 patients with NDMM at our center. Established a weighted MM prognostic scoring system risk model and validated its predicted PFS and OS by external cohort.

Results

Elevated lactate dehydrogenase levels (1 point), international staging system stage II/III (1 point), 1q21+ ≥ 52.75% (0.5 point), del (17p) ≥ 3.5% (0.5 point), and t (14;16) ≥ 35.25% (1 point) had independent prognostic significance. Patients were further divided into three risk groups: low (I) (score 0-0.5, 16.5%), intermed

SUBMITTER: Li Y 

PROVIDER: S-EPMC11536264 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature